October 2, 2014
The addition of pertuzumab to trastuzumab and docetaxel prolonged OS by nearly 16 months in patients with HER-2–positive metastatic breast cancer, according to final OS results of the CLEOPATRA study presented at the European Society for Medical Oncology Annual Congress in Madrid.
“The results of the CLEOPATRA study suggest that all patients who have newly diagnosed metastatic or advanced HER-2–positive breast cancer should be given the opportunity to have treatment with dual antibody therapy with trastuzumab and pertuzumab with chemotherapy,” Sandra M. Swain, MD, FACP, medical director of Washington Cancer Institute of the MedStar Washington Hospital Center, told HemOnc Today. “These results are phenomenal. We have not seen these kind of survival results in the metastatic disease setting in the past. The other very important aspect is that this could predict a mortality reduction in the adjuvant setting which will be reported in the APHINITY trial sometime in the next couple of years.”